Cell Source (Cell Source) Dividend Payout Ratio : 0.00 (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cell Source Dividend Payout Ratio?

Cell Source's dividend payout ratio for the months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for Cell Source's Dividend Payout Ratio or its related term are showing as below:

CLCS's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-29), the Dividend Yield % of Cell Source is 0.00%.

Cell Source's Dividends per Share for the months ended in Sep. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Cell Source Dividend Payout Ratio Historical Data

The historical data trend for Cell Source's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Dividend Payout Ratio Chart

Cell Source Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividend Payout Ratio

Get a 7-Day Free Trial

Cell Source Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cell Source's Dividend Payout Ratio

For the Biotechnology subindustry, Cell Source's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Cell Source's Dividend Payout Ratio falls into.

Cell Source Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Cell Source's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2022 )	/	EPS without NRI (A: Dec. 2022 )
	=	0	/	-0.18
	=	N/A

Cell Source's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.04
	=	N/A

Cell Source (OTCPK:CLCS) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Cell Source Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Cell Source's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Source (Cell Source) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website

https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.

Executives

George Verstraete	director	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave	director, 10 percent owner	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner	10 percent owner
Yoram Drucker	director	31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown	director	100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat	director, officer: CEO and CFO	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty	director	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman	director, 10 percent owner	C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines

From GuruFocus

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source's Scientific Advisory Board

By PRNewswire PRNewswire • 02-25-2021